JACC: CardioOncology will aim to publish the most impactful original research and state-of-the-art review articles pertaining to this rapidly emerging field. The journal will consist of original articles related to basic, translational, and clinical investigations in cardio-oncology. Topics of interest will include basic and translational mechanisms of cardiotoxicity; early diagnosis, risk stratification, prevention, and treatment of cardiotoxicity; and the multi-disciplinary care of cancer patients and survivors with cardiovascular risk factors and disease.
Ky will begin her five-year term as Editor-in-Chief in March 2019. She is an associate professor of medicine and epidemiology and a physician scientist at the Perelman School of Medicine at the University of Pennsylvania. She leads a highly active National Institutes of Health-funded translational research program in cardio-oncology and is the Principal Investigator of multiple cohort studies and clinical trials focused on the cardiotoxic effects of various cancer therapies. Her programmatic objectives are to understand how to improve cardiovascular outcomes in cancer patients by determining individual patient risk through detailed phenotyping of clinical characteristics, biologic markers and echocardiography-derived measures of myocardial mechanics and function.
Ky is also the founding director of the Penn Cardio-Oncology Center of Excellence, National Cancer Institute-funded ECOG ACRIN Cardiotoxicity Subcommittee Chair, and director of the Penn Center for Quantitative Echocardiography. She is an inducted member of the American Society of Clinical Investigation. She is also a section editor for cardio-oncology for JACC.
“It is a great honor to serve as the inaugural Editor-in-Chief of JACC: CardioOncology,” Ky said. “My vision is for the journal to play a vital and transformative role in advancing the cardiovascular care of a growing cancer population through the dissemination of knowledge and the education of providers who care for cancer patients.”